Role of Nrf2, HO-1 and GSH in neuroblastoma cell resistance to bortezomib

PLoS ONE

Volumn 11, Issue 3, 2016, Pages

  Furfaro, A L ^a   Piras, S ^b   Domenicotti, C ^b   Fenoglio, D ^c   De Luigi, A ^d   Salmona, M ^d   Moretta, L ^e   Marinari, U M ^b   Pronzato, M A ^b   Traverso, N ^b   Nitti, M ^b  

^a G GASLINI INSTITUTE   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^e BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CYSTEINE; GLUTAMATE CYSTEINE LIGASE; GLUTATHIONE; HEME OXYGENASE 1; PROTEASOME; RETINOIC ACID; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR NRF2; AMINO ACID TRANSPORTER; MESSENGER RNA; PROTEIN SUBUNIT; SLC7A11 PROTEIN, HUMAN;

ARTICLE; CANCER CELL; CELL VIABILITY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DRUG EFFICACY; GENE SEQUENCE; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LOW DRUG DOSE; NEUROBLASTOMA; NEUROBLASTOMA CELL; PROMOTER REGION; PROTEIN BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; UPREGULATION; WESTERN BLOTTING; ANTIOXIDANT RESPONSIVE ELEMENT; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; METABOLISM; PROTEIN SUBUNIT; TUMOR CELL LINE;

AMINO ACID TRANSPORT SYSTEM Y+; ANTIOXIDANT RESPONSE ELEMENTS; BORTEZOMIB; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GLUTAMATE-CYSTEINE LIGASE; GLUTATHIONE; HEME OXYGENASE-1; HUMANS; NEUROBLASTOMA; NF-E2-RELATED FACTOR 2; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN SUBUNITS; RNA, MESSENGER; TRANSCRIPTION, GENETIC; TRETINOIN; UP-REGULATION;

EID: 84962166023     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0152465     Document Type: Article

References (68)

1. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009;458(7239):780-3. doi: 10.1038/nature07733 PMID: 19194462
2. Gorrini C, Harris IS, Mak TW. Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov 2013;12(12):931-47. doi: 10.1038/nrd4002 PMID: 24287781
3. Traverso N, Ricciarelli R, Nitti M, Marengo B, Furfaro AL, Pronzato MA, et al. Role of glutathione in cancer progression and chemoresistance. Oxid Med Cell Longev 2013;2013:972913. doi: 10.1155/2013/972913 PMID: 23766865
4. Singh S, Khan AR, Gupta AK. Role of glutathione in cancer pathophysiology and therapeutic interventions. J Exp Ther Oncol 2012;9(4):303-16. PMID: 22545423
5. Jozkowicz A, Was H, Dulak J. Heme oxygenase-1 in tumors: is it a false friend? Antioxid Redox Signal 2007;9(12):2099-117. PMID: 17822372
6. Kim DS, Chae SW, Kim HR, Chae HJ. CO and bilirubin inhibit doxorubicin-induced cardiac cell death. Immunopharmacol Immunotoxicol 2009;31(1):64-70. doi: 10.1080/08923970802354762 PMID: 18756386
7. Alkhateeb AA, Connor JR. The significance of ferritin in cancer: anti-oxidation, inflammation and tumorigenesis. Biochim Biophys Acta 2013;1836(2):245-54. doi: 10.1016/j.bbcan. 2013.07.002 PMID: 23891969
8. Nuhn P, Kunzli BM, Hennig R, Mitkus T, Ramanauskas T, Nobiling R, et al. Heme oxygenase-1 and its metabolites affect pancreatic tumor growth in vivo. Mol Cancer 2009;8:37. doi: 10.1186/1476-4598-8-37 PMID: 19508729
9. Kobayashi M, Yamamoto M. Molecular mechanisms activating the Nrf2-Keap1 pathway of antioxidant gene regulation. Antioxid Redox Signal 2005;7(3-4):385-94. PMID: 15706085
10. Nguyen T, Nioi P, Pickett CB. The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J Biol Chem 2009;284(20):13291-5. doi: 10.1074/jbc. R900010200 PMID: 19182219
11. Numazawa S, Yoshida T. Nrf2-dependent gene expressions: a molecular toxicological aspect. J Toxicol Sci 2004;29(2):81-9. PMID: 15206576
12. Itoh K, Mimura J, Yamamoto M. Discovery of the negative regulator of Nrf2, Keap1: a historical overview. Antioxid Redox Signal 2010;13(11):1665-78. doi: 10.1089/ars.2010.3222 PMID: 20446768
13. Sekhar KR, Rachakonda G, Freeman ML. Cysteine-based regulation of the CUL3 adaptor protein Keap1. Toxicol Appl Pharmacol 2010;244(1):21-6. doi: 10.1016/j.taap. 2009.06.016 PMID: 19560482
14. Bryan HK, Olayanju A, Goldring CE, Park BK. The Nrf2 cell defence pathway: Keap1-dependent and -independent mechanisms of regulation. Biochem Pharmacol 2013;85(6):705-17. doi: 10.1016/j.bcp. 2012.11.016 PMID: 23219527
15. Hohn TJ, Grune T. The proteasome and the degradation of oxidized proteins: Part III-Redox regulation of the proteasomal system. Redox Biol 2014;2:388-94. doi: 10.1016/j.redox.2013.12.029 PMID: 24563857
16. Spataro V, Norbury C, Harris AL. The ubiquitin-proteasome pathway in cancer. Br J Cancer 1998;77(3):448-55. PMID: 9472642
17. Voorhees PM, Dees EC, O'Neil B, Orlowski RZ. The proteasome as a target for cancer therapy. Clin Cancer Res 2003;9(17):6316-25. PMID: 14695130
18. Joazeiro CA, Anderson KC, Hunter T. Proteasome inhibitor drugs on the rise. Cancer Res 2006;66(16):7840-2. PMID: 16861477
19. Adams J, Kauffman M. Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest 2004;22(2):304-11. PMID: 15199612
20. Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004;127(2):165-72. PMID: 15461622
21. Lara PN Jr, Davies AM, Mack PC, Mortenson MM, Bold RJ, Gumerlock PH, et al. Proteasome inhibition with PS-341 (bortezomib) in lung cancer therapy. Semin Oncol 2004;31(1 Suppl 1):40-6. PMID: 14981579
22. Edelman MJ. The potential role of bortezomib in combination with chemotherapy and radiation in nonsmallcell lung cancer. Clin Lung Cancer 2005;7 Suppl 2:S64-6. PMID: 16250930
23. Amato RJ. Renal cell carcinoma: review of novel single-agent therapeutics and combination regimens. Ann Oncol 2005;16(1):7-15. PMID: 15598929
24. Wright JJ. Combination therapy of bortezomib with novel targeted agents: an emerging treatment strategy. Clin Cancer Res 2010;16(16):4094-104. doi: 10.1158/1078-0432. CCR-09-2882 PMID: 20682705
25. Chen D, Frezza M, Schmitt S, Kanwar J, Dou QP. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr Cancer Drug Targets 2011;11(3):239-53. PMID: 21247388
26. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003;3(3):203-16. PMID: 12612655
27. Armstrong MB, Schumacher KR, Mody R, Yanik GA, Opipari AW Jr, Castle VP. Bortezomib as a therapeutic candidate for neuroblastoma. J Exp Ther Oncol 2008;7(2):135-45. PMID: 18771087
28. Pagnan G, Di Paolo D, Carosio R, Pastorino F, Marimpietri D, Brignole C, et al. The combined therapeutic effects of bortezomib and fenretinide on neuroblastoma cells involve endoplasmic reticulum stress response. Clin Cancer Res 2009;15(4):1199-209. doi: 10.1158/1078-0432. CCR-08-2477 PMID: 19228726
29. Aghajanian C, Soignet S, Dizon DS, Pien CS, Adams J, Elliott PJ, et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 2002;8(8):2505-11. PMID: 12171876
30. Miltenburg NC, Boogerd W. Chemotherapy-induced neuropathy: A comprehensive survey. Cancer Treat Rev 2014;40(7):872-82. doi: 10.1016/j.ctrv. 2014.04.004 PMID: 24830939
31. Zuccari G, Milelli A, Pastorino F, Loi M, Petretto A, Parise A, et al. Tumor vascular targeted liposomalbortezomib minimizes side effects and increases therapeutic activity in human neuroblastoma. J Control Release; 211:44-52. doi: 10.1016/j.jconrel.2015.05.286 PMID: 26031842
32. Furfaro AL, Piras S, Passalacqua M, Domenicotti C, Parodi A, Fenoglio D, et al. HO-1 up-regulation: a key point in high-risk neuroblastoma resistance to bortezomib. Biochim Biophys Acta 2014;1842(4):613-22. doi: 10.1016/j.bbadis.2013.12.008 PMID: 24380881
33. Raffaghello L, Prigione I, Bocca P, Morandi F, Camoriano M, Gambini C, et al. Multiple defects of the antigen-processing machinery components in human neuroblastoma: immunotherapeutic implications. Oncogene 2005;24(29):4634-44. PMID: 15897905
34. Airoldi I, Cocco C, Morandi F, Prigione I, Pistoia V. CXCR5 may be involved in the attraction of human metastatic neuroblastoma cells to the bone marrow. Cancer Immunol Immunother 2008;57(4):541-8. PMID: 17786442
35. Urru SA, Veglianese P, De Luigi A, Fumagalli E, Erba E, Gonella Diaza R, et al. A new fluorogenic peptide determines proteasome activity in single cells. J Med Chem 2010;53(20):7452-60. doi: 10.1021/jm100362x PMID: 20883027
36. Furfaro AL, Macay JR, Marengo B, Nitti M, Parodi A, Fenoglio D, et al. Resistance of neuroblastoma GI-ME-N cell line to glutathione depletion involves Nrf2 and heme oxygenase-1. Free Radic Biol Med 2012;52(2):488-96. doi: 10.1016/j.freeradbiomed.2011.11.007 PMID: 22142473
37. Piccirillo S, Filomeni G, Brune B, Rotilio G, Ciriolo MR. Redox mechanisms involved in the selective activation of Nrf2-mediated resistance versus p53-dependent apoptosis in adenocarcinoma cells. J Biol Chem 2009;284(40):27721-33. doi: 10.1074/jbc. M109.014837 PMID: 19643729
38. Fariss MW, Reed DJ. High-performance liquid chromatography of thiols and disulfides: dinitrophenol derivatives. Methods Enzymol 1987;143:101-9. PMID: 3657520
39. Furfaro AL, Nitti M, Marengo B, Domenicotti C, Cottalasso D, Marinari UM, et al. Impaired synthesis contributes to diabetes-induced decrease in liver glutathione. Int J Mol Med 2012;29(5):899-905. doi: 10.3892/ijmm.2012.915 PMID: 22344537
40. Sies H. Glutathione and its role in cellular functions. Free Radic Biol Med 1999;27(9-10):916-21. PMID: 10569624
41. Asensi M, Sastre J, Pallardo FV, Lloret A, Lehner M, Garcia-de-la Asuncion J, et al. Ratio of reduced to oxidized glutathione as indicator of oxidative stress status and DNA damage. Methods Enzymol 1999;299:267-76. PMID: 9916205
42. Thompson SA, White CC, Krejsa CM, Diaz D, Woods JS, Eaton DL, et al. Induction of glutamate-cysteine ligase (gamma-glutamylcysteine synthetase) in the brains of adult female mice subchronically exposed to methylmercury. Toxicol Lett 1999;110(1-2):1-9. PMID: 10593589
43. Patriarca S, Furfaro AL, Domenicotti C, Odetti P, Cottalasso D, Marinari UM, et al. Supplementation with N-acetylcysteine and taurine failed to restore glutathione content in liver of streptozotocin-induced diabetics rats but protected from oxidative stress. Biochim Biophys Acta 2005;1741(1-2):48-54. PMID: 15921899
44. Mauro L, Catalano S, Bossi G, Pellegrino M, Barone I, Morales S, et al. Evidences that leptin up-regulates E-cadherin expression in breast cancer: effects on tumor growth and progression. Cancer Res 2007;67(7):3412-21. PMID: 17409452
45. Zhang J, Ohta T, Maruyama A, Hosoya T, Nishikawa K, Maher JM, et al. BRG1 interacts with Nrf2 to selectively mediate HO-1 induction in response to oxidative stress. Mol Cell Biol 2006;26(21):7942-52. PMID: 16923960
46. Tan KP, Yang M, Ito S. Activation of nuclear factor (erythroid-2 like) factor 2 by toxic bile acids provokes adaptive defense responses to enhance cell survival at the emergence of oxidative stress. Mol Pharmacol 2007;72(5):1380-90. PMID: 17724089
47. Faraonio R, Vergara P, Di Marzo D, Pierantoni MG, Napolitano M, Russo T, et al. p53 suppresses the Nrf2-dependent transcription of antioxidant response genes. J Biol Chem 2006;281(52):39776-84. PMID: 17077087
48. Alam J, Igarashi K, Immenschuh S, Shibahara S, Tyrrell RM. Regulation of heme oxygenase-1 gene transcription: recent advances and highlights from the International Conference (Uppsala, 2003) on Heme Oxygenase. Antioxid Redox Signal 2004;6(5):924-33. PMID: 15345152
49. Wang XJ, Hayes JD, Henderson CJ, Wolf CR. Identification of retinoic acid as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha. Proc Natl Acad Sci U S A 2007;104(49):19589-94. PMID: 18048326
50. Itahana Y, Han R, Barbier S, Lei Z, Rozen S, Itahana K. The uric acid transporter SLC2A9 is a direct target gene of the tumor suppressor p53 contributing to antioxidant defense. Oncogene 2014.
51. Kim SS, Seong S, Lim SH, Kim SY. Biliverdin reductase plays a crucial role in hypoxia-induced chemoresistance in human glioblastoma. Biochem Biophys Res Commun 2013;440(4):658-63. doi: 10. 1016/j.bbrc.2013.09.120 PMID: 24113378
52. Kim SS, Seong S, Lim SH, Kim SY. Targeting biliverdin reductase overcomes multidrug resistance in leukemia HL60 cells. Anticancer Res 2013;33(11):4913-9. PMID: 24222129
53. McMahon M, Itoh K, Yamamoto M, Hayes JD. Keap1-dependent proteasomal degradation of transcription factor Nrf2 contributes to the negative regulation of antioxidant response element-driven gene expression. J Biol Chem 2003;278(24):21592-600. PMID: 12682069
54. Dreger H, Westphal K, Weller A, Baumann G, Stangl V, Meiners S, et al. Nrf2-dependent upregulation of antioxidative enzymes: a novel pathway for proteasome inhibitor-mediated cardioprotection. Cardiovasc Res 2009;83(2):354-61. doi: 10.1093/cvr/cvp107 PMID: 19351736
55. Yamamoto N, Sawada H, Izumi Y, Kume T, Katsuki H, Shimohama S, et al. Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease. J Biol Chem 2007;282(7):4364-72. PMID: 17158454
56. Kwak MK, Huang B, Chang H, Kim JA, Kensler TW. Tissue specific increase of the catalytic subunits of the 26S proteasome by indirect antioxidant dithiolethione in mice: enhanced activity for degradation of abnormal protein. Life Sci 2007;80(26):2411-20. PMID: 17521679
57. Lee S, Hur EG, Ryoo IG, Jung KA, Kwak J, Kwak MK. Involvement of the Nrf2-proteasome pathway in the endoplasmic reticulum stress response in pancreatic beta-cells. Toxicol Appl Pharmacol 2012;264(3):431-8. doi: 10.1016/j.taap. 2012.08.021 PMID: 22959925
58. Pickering AM, Linder RA, Zhang H, Forman HJ, Davies KJ. Nrf2-dependent induction of proteasome and Pa28alphabeta regulator are required for adaptation to oxidative stress. J Biol Chem 2012;287(13):10021-31. doi: 10.1074/jbc. M111.277145 PMID: 22308036
59. Na HK, Surh YJ. Oncogenic potential of Nrf2 and its principal target protein heme oxygenase-1. Free Radic Biol Med 2014;67:353-65. doi: 10.1016/j.freeradbiomed.2013.10.819 PMID: 24200599
60. Furfaro AL, Traverso N, Domenicotti C, Piras S, Moretta L, Marinari UM, et al. The Nrf2/HO-1 Axis in Cancer Cell Growth and Chemoresistance. Oxid Med Cell Longev 2016;2016:1958174. doi: 10.1155/2016/1958174 PMID: 26697129
61. Xue M, Momiji H, Rabbani N, Barker G, Bretschneider T, Shmygol A, et al. Frequency Modulated Translocational Oscillations of Nrf2 Mediate the Antioxidant Response Element Cytoprotective Transcriptional Response. Antioxid Redox Signal 2014.
62. Cullen SJ, Ponnappan S, Ponnappan U. Catalytic activity of the proteasome fine-tunes Brg1-mediated chromatin remodeling to regulate the expression of inflammatory genes. Mol Immunol 2009;47(2-3):600-5. doi: 10.1016/j.molimm.2009.09.008 PMID: 19800126
63. Huang CS, Chang LS, Anderson ME, Meister A. Catalytic and regulatory properties of the heavy subunit of rat kidney gamma-glutamylcysteine synthetase. J Biol Chem 1993;268(26):19675-80. PMID: 8103521
64. Fraser JA, Kansagra P, Kotecki C, Saunders RD, McLellan LI. The modifier subunit of Drosophila glutamatecysteine ligase regulates catalytic activity by covalent and noncovalent interactions and influences glutathione homeostasis in vivo. J Biol Chem 2003;278(47):46369-77. PMID: 12954617
65. Lu SC. Regulation of glutathione synthesis. Mol Aspects Med 2009;30(1-2):42-59. doi: 10.1016/j. mam.2008.05.005 PMID: 18601945
66. Miyazaki I, Murakami S, Torigoe N, Kitamura Y, Asanuma M. Neuroprotective effects of levetiracetam target xCT in astrocytes in parkinsonian mice. J Neurochem 2016;136(1):194-204. doi: 10.1111/jnc. 13405 PMID: 26485447
67. Wang H, Liu K, Geng M, Gao P, Wu X, Hai Y, et al. RXRalpha inhibits the NRF2-ARE signaling pathway through a direct interaction with the Neh7 domain of NRF2. Cancer Res 2013;73(10):3097-108. doi: 10.1158/0008-5472. CAN-12-3386 PMID: 23612120
68. Valenzuela M, Glorieux C, Stockis J, Sid B, Sandoval JM, Felipe KB, et al. Retinoic acid synergizes ATO-mediated cytotoxicity by precluding Nrf2 activity in AML cells. Br J Cancer 2014;111(5):874-82. doi: 10.1038/bjc.2014.380 PMID: 25003661